Holen Sie sich die Stockscreener-App
199.33
0.86%
-1.73
Handel nachbörslich:
199.33
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After New Neurology Data Plans At 2026 AAN Meeting - simplywall.st
Jazz Pharmaceuticals enters exclusive licensing deal with Saniona - MSN
Jazz Pharmaceuticals to Present Xywav Narcolepsy Data at 2026 AAN Annual Meeting - Sleep Review
Whats the RSI of Jazz Pharmaceuticals plc stockMarket Trend Review & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Bond Watch: Will CNH Industrial NV outperform its industry peers2026 News Drivers & Precise Swing Trade Alerts - baoquankhu1.vn
Is It Too Late To Consider Jazz Pharmaceuticals (JAZZ) After A 93% One Year Rally? - simplywall.st
Why Jazz Pharmaceuticals Stock’s EPS is Set to 3x in 2026 - TIKR.com
Does New Epidiolex Behavioral Data at AAN 2026 Reframe Jazz Pharmaceuticals’ (JAZZ) Neuroscience Strategy? - simplywall.st
Is Jazz Pharmaceuticals plc exposed to political risk2026 Bull vs Bear & Low Volatility Stock Recommendations - baoquankhu1.vn
Jazz Pharmaceuticals PLC Stock Intrinsic Values - GuruFocus
Jazz Pharmaceuticals (JAZZ) Receives Outperform Rating with New Price Target - GuruFocus
Is Jazz Pharmaceuticals (JAZZ) one of the best cheap biotech stocks to buy now? - MSN
Jazz Pharmaceuticals stock hits all-time high at 198.01 USD By Investing.com - Investing.com Australia
Patterns Watch: Is Jazz Pharmaceuticals plc exposed to political riskMarket Rally & Capital Efficiency Focused Ideas - baoquankhu1.vn
Raymond James initiates Jazz Pharmaceuticals stock coverage with outperform rating - Investing.com UK
Jazz Pharmaceuticals stock hits all-time high at 198.01 USD - Investing.com
Asparaginase Market Key Companies AnalysisServier - openPR.com
Jazz Pharmaceuticals Presents Research at AAN Annual Meeting on Rare Neurological Disorders - Intellectia AI
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting - PR Newswire
Jazz Pharmaceuticals PLC Stock Warning Signs | BSP:J2AZ34 - GuruFocus
Who's Buying or Selling Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Today? - GuruFocus
Jazz Pharmaceuticals PLC Stock Operating Data - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Earnings Transcripts - GuruFocus
Jazz Pharmaceuticals PLC Stock Historical Valuations | BSP:J2AZ34 - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Competitors 2026 - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Price & 30 Year Financial Data - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Dividend - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock News, Headlines & Updates - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Valuation: Modestly Overvalued - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) DCF Valuation - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Price, Trades & News - GuruFocus
Decliners Report: Is Jazz Pharmaceuticals plc subject to activist investor interest2026 Winners & Losers & Safe Entry Point Identification - baoquankhu1.vn
Jazz Pharmaceuticals PLC R (J7Z.HM) Q2 FY2025 earnings call transcript - Yahoo Finance
Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Barchart.com
Epilepsy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharma, SK Biopharma - Barchart.com
Jazz projects $4.25B–$4.50B 2026 revenue while advancing rare disease and oncology launches - MSN
Autistic Disorder Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Bioscienc - Barchart.com
Jazz Pharmaceuticals plc (JAZZ) reports $1.2 billion Q4 revenue, beats $1.17B estimate - MSN
Rate Cut: Whats the RSI of Jazz Pharmaceuticals plc stockWeekly Stock Report & Stepwise Swing Trade Plans - baoquankhu1.vn
Capricorn Fund Managers Ltd Purchases New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Why is Jazz (JAZZ) down 3.9% since last earnings report? - MSN
Jazz Pharmaceuticals PLC (J7Z.HM) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
JAZZ Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Perpetual Ltd Lowers Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC (J7Z.HM) stock major holders - Yahoo Finance Singapore
Jazz Pharmaceuticals PLC (J7Z.HM) stock price, news, quote and history - Yahoo Finance Singapore
Insider Sell: Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals PLC (JAZZ) - GuruFocus
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - uk.finance.yahoo.com
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 6,000 Shares of Stock - MarketBeat
Director at Jazz Pharmaceuticals (JAZZ) sells 6,000 company shares - Stock Titan
JAZZ Stock Price, Quote & Chart | JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) - ChartMill
Jazz Pharmaceuticals PLC (J7Z.HM) insider ownership and holdings - Yahoo Finance Singapore
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference - aijourn.com
Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts - Yahoo Finance
Jazz Pharmaceuticals (NASDAQ: JAZZ) Form 144 shows 6,000-share sale notice - Stock Titan
Retirement Systems of Alabama Cuts Stock Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):